Equities research analysts forecast that Profound Medical Corp. (NASDAQ:PROF – Get Rating) will report earnings of ($0.40) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Profound Medical’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.41). Profound Medical posted earnings of ($0.35) per share during the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Profound Medical will report full-year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.60) to ($0.94). For the next financial year, analysts anticipate that the company will post earnings of ($1.00) per share, with EPS estimates ranging from ($1.49) to ($0.46). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Profound Medical.
Profound Medical (NASDAQ:PROF – Get Rating) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $2.80 million. Profound Medical had a negative net margin of 417.41% and a negative return on equity of 37.74%. During the same period last year, the firm earned ($0.38) EPS.
NASDAQ PROF traded up $0.47 during trading hours on Tuesday, reaching $7.07. The company’s stock had a trading volume of 97,587 shares, compared to its average volume of 54,610. The firm has a market capitalization of $146.91 million, a price-to-earnings ratio of -4.62 and a beta of 1.11. Profound Medical has a 1-year low of $6.09 and a 1-year high of $19.32. The company’s 50-day moving average is $8.16 and its two-hundred day moving average is $9.65.
A number of institutional investors have recently modified their holdings of PROF. CVI Holdings LLC acquired a new position in Profound Medical during the third quarter worth $146,000. D. E. Shaw & Co. Inc. acquired a new position in Profound Medical during the fourth quarter worth $121,000. Harbor Advisors LLC acquired a new position in Profound Medical during the fourth quarter worth $139,000. Jane Street Group LLC acquired a new position in Profound Medical during the first quarter worth $132,000. Finally, Wealth Management Partners LLC acquired a new position in Profound Medical during the first quarter worth $230,000. Institutional investors own 60.23% of the company’s stock.
About Profound Medical (Get Rating)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.
- Get a free copy of the StockNews.com research report on Profound Medical (PROF)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.